Switching from latanoprost or travoprost ophthalmolic solution to tafruprost and timolol fixed ophthalmic solution

Switching from latanoprost or travoprost ophthalmolic solution to tafruprost and timolol fixed ophthalmic solution - Switching from latanoprost or travoprost to tafruprost and timolol fixed ophthalmic solution

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015823

Enrollment

Registered

2014-12-05

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open angle glaucoma and ocular hypertension

Interventions

Switching from latanoprost or travoprost monotherapy to tafluprost/timolol fixed combination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary open angle glaucoma Ocular hypertension

Exclusion criteria

Exclusion criteria: Severe respiratory diseases Severe systemic diseases Allegic reaction against contents of the experimental compounds

Design outcomes

Primary

Measure	Time frame
Reduction of intraocular pressure Topical and systemic adverse effects	—

Countries

Japan

Contacts

Public ContactKenji Kashiwagi

University of Yamanashi Ophthalmology

kenjik@yamanashi.ac.jp055-273-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026